Type 2 Diabetes Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Hanmi Pharmaceuticals, Sanofi, Eli lily and Company, AstraZeneca, NovoNordisk, Noxxon Pharma AG, and others.
DelveInsight’s, “Type 2 Diabetes Mellitus Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Type 2 Diabetes mellitus pipeline landscape. It covers the Type 2 Diabetes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Type 2 Diabetes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Type 2 Diabetes Pipeline Report
- DelveInsight’s Type 2 Diabetes pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Type 2 Diabetes treatment.
- The leading companies working in the Type 2 Diabetes Market include Hanmi Pharmaceuticals, Sanofi, Eli lily and Company, AstraZeneca, NovoNordisk, Noxxon Pharma AG, Oramed Pharmaceuticals, Lexicon Pharmaceuticals, Daiichi Sankyo Company, Halozyme Therapeutics, Saniona, Novartis, Pfizer, Merck Sharp & Dohme Corp., Mylan, Nordic Bioscience A/S, KeyBioscience AG, Adocia, Jiangsu Hengrui Medicine, Bristol myers Suibb, Phenomix, Forest Laboratories, ACADIA Pharmaceuticals, Hanmi Pharmaceuticals, Cytogel, Ligand Pharmaceuticals, Arthritis Innovation Corporation, Astellas Pharma, IItoo Pharma, Medspace Inc., Oramed Ltd., Flexion Therapeutics, Integrium, AbbVie, and others.
- Promising Type 2 Diabetes Pipeline Therapies in the various stages of development include Muraglitazar, Pioglitazone, Cotadutide, ORMD-0801 (qd), glargine, detemir, saxagliptin, sitagliptin, and others.
- November 2023: Prokidney announced a study of Phase 3 clinical trials for Renal Autologous Cell Therapy (REACT). The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.
- November 2023: Merck Sharp & Dohme LLC announced a study of Phase 3 clinical trials for Ertugliflozin 5 mg and Metformin. This study will evaluate the safety and efficacy of ertugliflozin (MK-8835) in pediatric participants with T2DM on metformin with/without insulin. The primary hypothesis of the study is that the addition of ertugliflozin reduces hemoglobin A1C (HbA1C) more than the addition of placebo after 24 weeks of treatment.
Request a sample and discover the recent advances in Type 2 Diabetes Treatment Drugs @ Type 2 Diabetes Pipeline Outlook Report
The Type 2 Diabetes pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Type 2 Diabetes drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Type 2 Diabetes clinical trial landscape.
Type 2 Diabetes Overview
Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia. It may be due to impaired insulin secretion, resistance to peripheral actions of insulin, or both. Diabetes mellitus are of three types Type1, Type 2 and Gestational Diabetes.
Find out more about Type 2 Diabetes Treatment Landscape @ Drugs for Type 2 Diabetes Treatment
Type 2 Diabetes Emerging Drugs Profile
- Sotagliflozin: Lexicon Pharmaceuticals
- ORMD0801: Oramed Pharmaceuticals
- LY3209590-Eli lily and Company
- HM12460A: Hanmi Pharmaceuticals
- HM14220:Hanmi Pharmaceuticals
Type 2 Diabetes Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the therapies for Postoperative Pain. The Type 2 Diabetes companies which have their Postoperative Pain drug candidates in the most advanced stage, i.e. phase III include, Lexicon Pharmaceuticals.
DelveInsight’s Type 2 Diabetes pipeline report covers around 100+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Type 2 Diabetes mellitus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Learn more about the emerging Type 2 Diabetes Pipeline Therapies @ Type 2 Diabetes Clinical Trials Assessment
Scope of the Type 2 Diabetes Pipeline Report
- Coverage- Global
- Type 2 Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Type 2 Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Type 2 Diabetes Companies- Hanmi Pharmaceuticals, Sanofi, Eli lily and Company, AstraZeneca, NovoNordisk, Noxxon Pharma AG, Oramed Pharmaceuticals, Lexicon Pharmaceuticals, Daiichi Sankyo Company, Halozyme Therapeutics, Saniona, Novartis, Pfizer, Merck Sharp & Dohme Corp., Mylan, Nordic Bioscience A/S, KeyBioscience AG, Adocia, Jiangsu Hengrui Medicine, Bristol myers Suibb, Phenomix, Forest Laboratories, ACADIA Pharmaceuticals, Hanmi Pharmaceuticals, Cytogel, Ligand Pharmaceuticals, Arthritis Innovation Corporation, Astellas Pharma, IItoo Pharma, Medspace Inc., Oramed Ltd., Flexion Therapeutics, Integrium, AbbVie, and others.
- Type 2 Diabetes Pipeline Therapies- Muraglitazar, Pioglitazone, Cotadutide, ORMD-0801 (qd), glargine, detemir, saxagliptin, sitagliptin, and others.
Dive deep into rich insights for new drugs for Type 2 Diabetes treatment, Visit @ Type 2 Diabetes Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Type 2 Diabetes mellitus: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Type 2 Diabetes mellitus – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Sotagliflozin: Lexicon Pharmaceuticals
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- LY3209590: Eli lily and Company
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- HM12460A: Hanmi Pharmaceuticals
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- HM14220: Hanmi Pharmaceuticals
- Drug profiles in the detailed report…..
- Inactive Products
- Type 2 Diabetes mellitus- Key Companies
- Type 2 Diabetes mellitus- Key Products
- Type 2 Diabetes mellitus – Unmet Needs
- Type 2 Diabetes mellitus – Market Drivers and Barriers
- Type 2 Diabetes mellitus – Future Perspectives and Conclusion
- Type 2 Diabetes mellitus Analyst Views
- Type 2 Diabetes mellitus Key Companies
- Appendix
For further information on the Type 2 Diabetes pipeline therapeutics, reach out @ Type 2 Diabetes Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/familial-lipoprotein-lipase-deficiency-market
